HC Wainwright Issues Negative Forecast for Immunome Earnings

Key Points

• HC Wainwright lowered its Immunome earnings forecasts, projecting a Q3 2026 loss of $0.65 per share versus its prior estimate of $0.51. It maintained a Buy rating despite forecasting losses through 2028.
• Immunome reported a quarterly loss of $0.65 per share, missing the $0.51 analyst consensus, while shares opened at $26.42 after falling 5.6%.
• Analyst sentiment remains broadly positive: 12 analysts rate the stock Buy and one rates it Sell, producing a Moderate Buy consensus and a $34.64 average price target. However, insiders sold 682,310 shares worth about $15.7 million over the past 90 days.

Immunome, Inc. (NASDAQ:IMNM - Free Report) - Research analysts at HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for Immunome in a research report issued on Wednesday, August 12th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($0.65) for the quarter, down from their previous forecast of ($0.51). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Immunome's current full-year earnings is ($2.06) per share. HC Wainwright also issued estimates for Immunome's Q4 2026 earnings at ($0.68) EPS, FY2026 earnings at ($2.45) EPS, FY2027 earnings at ($2.11) EPS, FY2028 earnings at ($0.85) EPS, FY2029 earnings at $0.40 EPS and FY2030 earnings at $1.08 EPS.

A number of other equities research analysts have also weighed in on the stock. Wedbush lifted their target price on shares of Immunome from $31.00 to $35.00 and gave the company an "outperform" rating in a research note on Wednesday. Truist Financial raised their price objective on shares of Immunome from $37.00 to $38.00 and gave the stock a "buy" rating in a report on Wednesday. Citigroup reiterated a "buy" rating on shares of Immunome in a report on Thursday, July 9th. Leerink Partners decreased their target price on Immunome from $37.00 to $33.00 and set an "outperform" rating for the company in a research report on Friday, May 15th. Finally, Barclays assumed coverage on Immunome in a research note on Thursday, May 28th. They issued an "overweight" rating and a $36.00 target price for the company. Twelve research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Immunome has a consensus rating of "Moderate Buy" and a consensus price target of $34.64.

Immunome Stock Down 5.6%

NASDAQ:IMNM opened at $26.42 on Friday. The firm's fifty day simple moving average is $22.02 and its 200 day simple moving average is $22.20. The stock has a market cap of $3.00 billion, a P/E ratio of -10.44 and a beta of 2.08. Immunome has a twelve month low of $8.66 and a twelve month high of $28.62.

Immunome (NASDAQ:IMNM - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.14).

Insider Buying and Selling

In related news, insider Kinney Horn sold 90,616 shares of the firm's stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $25.09, for a total transaction of $2,273,555.44. Following the completion of the sale, the insider owned 50,366 shares of the company's stock, valued at $1,263,682.94. This trade represents a 64.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Max Rosett sold 60,000 shares of the business's stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $18.23, for a total transaction of $1,093,800.00. Following the completion of the transaction, the chief financial officer owned 54,037 shares of the company's stock, valued at approximately $985,094.51. The trade was a 52.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 682,310 shares of company stock worth $15,675,566 in the last 90 days. 7.21% of the stock is owned by company insiders.

Institutional Trading of Immunome

Institutional investors and hedge funds have recently modified their holdings of the business. Creative Planning lifted its holdings in shares of Immunome by 4.0% during the third quarter. Creative Planning now owns 18,664 shares of the company's stock valued at $219,000 after purchasing an additional 710 shares in the last quarter. Russell Investments Group Ltd. increased its position in Immunome by 14.4% during the fourth quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company's stock valued at $159,000 after acquiring an additional 935 shares during the last quarter. Allworth Financial LP purchased a new stake in Immunome during the second quarter valued at $25,000. California State Teachers Retirement System lifted its holdings in Immunome by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 67,012 shares of the company's stock valued at $1,439,000 after acquiring an additional 1,167 shares during the period. Finally, Assetmark Inc. lifted its holdings in Immunome by 46.6% in the first quarter. Assetmark Inc. now owns 4,535 shares of the company's stock valued at $99,000 after acquiring an additional 1,442 shares during the period. Institutional investors own 44.58% of the company's stock.

Trending Headlines about Immunome

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: Analyst support and potential catalysts remain significant. Truist raised its price target to $38 from $37 and reiterated a Buy rating. Separately, Immunome’s varegacestat NDA has been accepted by the FDA, with a PDUFA decision expected in April 2027. The company also expects initial 2026 data from its Phase 1 IM-1021 ROR1 antibody-drug conjugate program. Truist price target update Immunome clinical catalysts analysis
• Positive Sentiment: Institutional ownership provides a supportive backdrop. BlackRock established an approximately $186.6 million position, while T. Rowe Price and Primecap increased their holdings. Institutional investors collectively own about 44.6% of Immunome’s shares, indicating substantial professional-investor interest in the pipeline.
• Neutral Sentiment: Director selling adds a supply concern but was conducted under a Rule 10b5-1 plan. Director Isaac Barchas sold roughly 98,700 shares from August 10–12 for approximately $2.6 million, reducing his direct holdings to 92,211 shares. The pre-arranged nature of the transactions makes them a less definitive signal about his current outlook. Immunome director SEC filing
• Negative Sentiment: Earnings and estimates are weighing on sentiment. Immunome reported a second-quarter loss of $0.65 per share, wider than the $0.51 consensus estimate. HC Wainwright subsequently reduced its Q3 2026 estimate to a $0.65 loss from $0.51, cut Q4 to a $0.68 loss from $0.53, and lowered full-year 2026 and 2027 estimates to losses of $2.45 and $2.11 per share, respectively. The report triggered a gap lower after earnings, despite HC Wainwright maintaining its Buy rating. Immunome second-quarter results Immunome shares gap down after earnings miss

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome's approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company's lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source